Back to catalogue
№ 029 24 filings · 2021-04-22 → 2026-01-20

AVACTA GROUP PLC

AVCT
Health Care Market cap £341m Overall fit 165 /1000

Poor fit for the investor profile: minimal AI-receiver exposure (Avacta uses Tempus AI rather than benefiting from AI spending), valuation appears full-to-stretched on a binary partnership thesis, operating leverage exists only as deal optionality not as scalable revenue, and downside protection is weak given <9 months cash, recurring dilution and a convertible-bond overhang.

Fair value range 30p–65p Mid case · £210m
Absolute upside -38.5% vs current market cap
Conviction 2/5 confidence in overvalued call
Supports the call
  • Clear disclosure of cash, convert terms and clinical milestones
  • Observable Phase 1b efficacy signal in SGC cohort
  • Identifiable cost base allows runway/burn modelling
Limits the call
  • Valuation dominated by binary partnership optionality not derivable from filings
  • No revenue or recent comparable transaction to anchor a multiple; further dilution likely
Methodology

Risk-adjusted platform NPV / partnership optionality, net of dilution

In one line · bull case

Differentiated tumour-activated PDC platform with early clinical proof points and active pharma dialogue that could re-rate the stock on a major partnership deal.

In one line · biggest risk

Sub-9-month cash runway combined with a structurally dilutive convertible bond means equity holders are likely to be diluted before any value-crystallising partnership closes.

Drivers
AI beneficiary 15 /100
Uses Tempus AI to select trial indications — a customer of AI, not a beneficiary; value flows to the tools vendor.
Operating leverage 55 /100
Fixed-cost R&D platform with no revenue means any partnership upfront drops near-fully to operating profit, but this is deal-binary not scalable.
Earnings vs expectations 35 /100
Clinical milestones broadly delivered with multi-year slippage on AVA6103 IND; financing milestones consistently met only via dilution.
Growth momentum 30 /100
Revenue from continuing operations is de minimis and effectively flat; losses widening on lower group base post-divestment.
Moat 45 /100
Patented FAP-cleavable peptide platform with growing IP estate but moat is unproven without a commercialised product.
Earnings quality 30 /100
Heavy share-based payment charges, complex convertible-derivative fair-value movements, repeated impairments distort reported numbers.
Management quality 35 /100
New CEO since 2024; prior M&A in diagnostics destroyed material capital (acquired £34m+ headline, divested c.£15m); >20% against vote on 2025 remuneration resolution.
Cyclicality 25 /100
Clinical-stage biotech demand is defensive but funding access is highly capital-markets sensitive.
Leverage 60 /100
£23m convertible bond outstanding, conversion price reset to 75p, deferred but with bondholder acceleration rights from Oct-2026.
Value-trap signals · 6
  • Repeated equity dilution at progressively lower prices
  • Diagnostics divestment crystallised loss vs. acquisition cost
  • Cash runway statements repeatedly extended only via fresh raises
  • Convertible bond renegotiated twice; accelerator rights from Oct-2026
  • Slippage in AVA6103 IND timing from 2023 to Q1 2026
  • Notable shareholder dissent (>20%) on 2025 AGM Resolution 2

AVACTA GROUP PLC (AVCT) — Investment Research Note

Executive summary

Avacta is a clinical-stage UK biopharmaceutical company developing pre|CISION®, a tumour-activated drug-delivery platform that uses the FAP enzyme to release cytotoxic payloads selectively in the tumour microenvironment, with two clinical assets — faridoxorubicin (AVA6000) in Phase 1b expansion and FAP-Exd (AVA6103) entering Phase 1 in Q1 2026. The operating trajectory over the 5-year window covered is one of expanding R&D spend (£14.3m FY24), recurring £20-30m annual losses, repeated equity raises (£31.1m in 2024, £22.5m in 2025), the divestment of the diagnostics division (acquired for £34m+, ultimately disposed for c.£15m proceeds), and a chronic financing overhang from a 2022 senior unsecured convertible bond originally £55m. The single most important point for valuation today is that at £337.7m market cap, the equity is being valued largely on the optionality of pre|CISION® partnering — with only £16.9m cash and runway into Q3 2026, holders should expect further dilution before any value-crystallising deal.

Fair value estimate

  • Methodology: Sum-of-parts / risk-adjusted NPV of platform optionality. There are no current revenues to anchor a multiple, no near-term path to profitability, and no announced partnership deal to anchor a comparable transaction value, so this is an indicative range only.
  • Key assumptions:
    • Pre|CISION® platform partnership value (faridoxorubicin SGC indication + FAP-Exd): assume £150–250m risk-adjusted enterprise value, anchored on Phase 1b SGC efficacy signals (90% disease control rate per Jan-2026 update) and the FAP-Exd preclinical/IND data, applying typical Phase 1/2 oncology asset values heavily probability-weighted (10–20% PoS).
    • Net cash adjustment: £16.9m cash less £22.95m convertible bond par (now deferred to Oct-2027 but with reset conversion at 75p creating dilution risk) — effectively net debt of c.£6m after H1-2026 spend.
    • Share count: 436.4m post-Nov-2025 placing, but assume further 50-100m dilution through to a partnering event (Q3-2026 raise + convert settlement).
  • Fair value range: 30p – 65p per share, implying a market cap range of £130m – £285m (mid-point c.£210m).
  • Current market cap: £337.7m (implied price c.77p).
  • Absolute downside to mid-point: c.-38%. View: overvalued.

Sector context

  • Confirmed sector: Health Care (clinical-stage biopharma, ICB Health Care super-sector).
  • Quality/growth/leverage profile vs. AIM/LSE clinical-stage oncology peers: below typical peer quality. Shorter cash runway (<9 months on current burn at year-end 2025), recurring dilutive convertible settlements, and the recent loss-making divestment of the diagnostics arm all weigh against the platform thesis.
  • Listed peers: Bicycle Therapeutics (Nasdaq: BCYC, similar tumour-targeted peptide-drug-conjugate platform), Crescendo Biologics (private comp), Hutchmed (LSE: HCM, oncology). Bicycle is the closest pure listed comparator — it is well-funded with multi-hundred-million-dollar pharma deals, highlighting what a successful execution looks like and how much remains to be proven at Avacta.

Investment thesis (3 bullets)

  • Differentiated, validated tumour-activated platform. Phase 1b salivary gland cancer cohort (n at full readout) showed a 90% disease control rate, with biopsy data confirming intratumoural release; cardiac safety markedly better than conventional doxorubicin. This is a tangible clinical proof-point for the platform mechanism, not just preclinical narrative 2026-01-20 year-end trading update; 2025-09-30 H1 2025 results.
  • Second clinical asset entering Q1 2026 with derisked design. FAP-Exd (AVA6103, exatecan payload) starts Phase 1 in Q1 2026 in four AI-selected indications (Tempus collaboration), using parallel Q2W/Q3W arms and BOIN dose-finding — a faster, more capital-efficient design than the AVA6000 trial. Management retains 100% economics pending readouts 2026-01-20 trading update.
  • Active partnering dialogue with global pharma. Management notes "multiple conversations with global pharmaceutical companies regarding our full pipeline" with potential partners watching the maturing SGC survival data and the AVA6103 IND. A single transformative deal would re-rate the equity sharply 2026-01-20 trading update; 2025-09-30 H1 results.

Key risks (3 bullets)

  • Cash runway is short and dilution is structural. £16.9m cash at 31-Dec-2025, runway only into Q3 2026 on current spend; convertible bond reset at 75p (deferred but accelerating from Oct-2026) creates persistent share issuance risk. The Nov-2025 placing of 25.4m shares already absorbed near-term capacity, and the FY24 loss-per-share was 8.54p continuing ops 2025-09-30 H1 2025 results; 2025-11-03 completion of placing.
  • No partnership has yet materialised despite years of dialogue. Management has signalled partner interest in pre|CISION® since 2023 (LG Chem, Daewoong/AffyXell, POINT Biopharma deals all pre-date the current strategy and have not delivered material near-term value to Avacta). Continued dependence on partnering means the bull case is binary on a deal that has repeatedly failed to close at scale 2023-09-28 H1 2023 results; 2024-04-30 FY23 results.
  • Capital-allocation track record is poor. Diagnostics division built via two acquisitions (Launch £24m+£13m earnout in 2022, Coris £7.3m+£3m earnout in 2023), then divested for total upfront proceeds c.£15m (Launch sale + Coris £2.15m) — a clear admission that the prior M&A strategy destroyed value. Impairment charges of £23m+ were taken in FY24 2024-04-30 FY23 results; 2025-09-30 H1 2025 results.

Operating leverage

Avacta is a pure-platform biotech now: continuing-operations cost base is dominated by R&D (£7.2m H1 2025, c.£14m FY24) and central SG&A (£4.5m H1 2025). Revenue from continuing operations is de minimis (£56k H1 2025) — there is no current operating leverage as reported, because there is no incremental revenue. The leverage that matters here is deal leverage: a typical clinical-stage oncology partnership for a Phase 2-ready PDC programme delivers $50-150m upfront and $200-500m+ in development milestones. Because the cost base is largely fixed and Avacta has no commercial infrastructure, any partnership upfront would translate to near-100% incremental operating margin in the year received. That said, partnerships for early-clinical assets typically trade slowly and at lower upfronts than headline figures suggest; the user's "long-tail upside" framework applies here only in a binary, optionality-style way — not in the SaaS-like, capacity-constrained sense the investor profile favours 2025-09-30 H1 2025 results.

Value-trap signals

  • Repeated equity dilution at progressively lower prices (placing prices 50p in 2024, recent convert reset to 75p).
  • Diagnostics divestment crystallised a material loss vs. acquisition prices, raising questions about prior strategic judgement.
  • Cash runway has been "into Q1 2026 / Q3 2026" repeatedly across filings — i.e. each raise extends survival by 9-12 months, not to a clear value-crystallising event.
  • Convertible bond renegotiated twice; bondholder has the right to accelerate from Oct-2026, capping equity upside on any positive readout.
  • 22.75% against vote on Resolution 2 at the 2025 AGM (remuneration-related) signals shareholder discontent 2025-07-02 result of AGM.
  • Operating losses widening on lower revenue base post-diagnostics divestment.

Earnings vs. expectations

Avacta does not publish forward financial guidance in the manner that consensus-tracking software companies do — it sets clinical milestones (first patient dosed dates, data readouts, IND filings) and cash-runway statements. Against those:

  • AVA6000 first patient dosed Aug-2021, broadly on guided timelines 2021-09-30 H1 2021.
  • Phase 1a SGC data delivered to ESMO 2025 on schedule; Phase 1b expansion enrolling 2025-09-30 H1 2025.
  • AVA6103 IND has slipped from initial "2023" mentions in 2022 filings to "Q1 2026" in current filings — i.e., a multi-year slippage 2022-09-29 H1 2022; 2026-01-20 trading update.
  • Cash runway guidance has been repeatedly extended via fresh equity raises rather than achieved on plan.

Pattern: clinical milestones mostly delivered (with some slippage), but financing milestones have consistently required dilution rather than partnership monetisation.

Conviction

Conviction: 2 (low).

  • Anchors: clear disclosure of cash position and convertible-bond terms; clinical-data milestones are reasonably well documented; market cap is observable.
  • Limits: (1) fair value is dominated by partnership optionality whose probability and value are unknowable from filings; (2) there is no observable revenue stream or comparable transaction to anchor a multiple; (3) future dilution is highly likely but its magnitude and price are unpredictable. A different methodology (e.g., pure risk-adjusted DCF with Phase 2/3 PoS) could land at materially different numbers — anywhere from £80m (writedown scenario) to £500m+ (deal-success scenario).
Filings consulted · 25

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-01-20Year End Trading Update2026-01-20_9367834_year-end-trading-update.md0.85
  2. 2025-11-03Completion OF Placing And Tvr2025-11-03_9208439_completion-of-placing-and-tvr.md0.59
  3. 2025-10-23Notice OF Investor Presentation2025-10-23_9190790_notice-of-investor-presentation.md0.59
  4. 2025-09-30Interim Half Year Results 20252025-09-30_9138746_interim-half-year-results-2025.md0.77
  5. 2025-09-15Notice OF Interim Results2025-09-15_9106990_notice-of-interim-results.md0.77
  6. 2025-07-02Result OF Agm2025-07-02_8960814_result-of-agm.md0.26
  7. 2025-06-09Posting OF Annual Report And Revised Notice OF Agm2025-06-09_8920282_posting-of-annual-report-and-revised-notice-of-agm.md0.81
  8. 2025-03-31Avacta Quarterly Update2025-03-31_8804153_avacta-quarterly-update.md0.55
  9. 2024-09-30Interim Results2024-09-30_8448144_interim-results.md0.58
  10. 2024-06-26Result OF Agm2024-06-26_8280211_result-of-agm.md0.20
  11. 2024-05-31Posting OF Annual Report And Notice OF Agm2024-05-31_8233243_posting-of-annual-report-and-notice-of-agm.md0.62
  12. 2024-04-30Full Year Results2024-04-30_8163417_full-year-results.md0.45
  13. 2024-02-29Result OF Placing2024-02-29_8062234_result-of-placing.md0.32
  14. 2023-09-28Interim Results For The Period Ending 30 June 20232023-09-28_7782624_interim-results-for-the-period-ending-30-june-2023.md0.41
  15. 2023-06-02Posting OF Annual Report And Notice OF Agm2023-06-02_7556382_posting-of-annual-report-and-notice-of-agm.md0.43
  16. 2023-04-03Notice OF Results And Investor Presentation2023-04-03_7424293_notice-of-results-and-investor-presentation.md0.17
  17. 2022-10-18Result OF Placing2022-10-18_7382449_result-of-placing.md0.17
  18. 2022-10-18Proposed Acquisition OF Launch Diagnostics2022-10-18_7352192_proposed-acquisition-of-launch-diagnostics.md0.19
  19. 2022-09-29Interim Results For The Period Ended 30 June 20222022-09-29_7168995_interim-results-for-the-period-ended-30-june-2022.md0.23
  20. 2022-05-31Posting OF Annual Report And Notice OF Agm2022-05-31_7074624_posting-of-annual-report-and-notice-of-agm.md0.24
  21. 2022-03-30Notice OF Results And Investor Presentation2022-03-30_7093986_notice-of-results-and-investor-presentation.md0.17
  22. 2021-09-30Interim Results For The Period Ended 30 June 20212021-09-30_6598819_interim-results-for-the-period-ended-30-june-2021.md0.23
  23. 2021-06-28Result OF Agm2021-06-28_6467612_result-of-agm.md0.07
  24. 2021-05-25Posting OF Annual Report And Notice OF Agm2021-05-25_6483683_posting-of-annual-report-and-notice-of-agm.md0.24
  25. 2021-04-22Final Results2021-04-22_6545540_final-results.md0.10

This research note was authored by a large language model after reading 24 regulatory filings published between 2021-04-22 and 2026-01-20. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.